The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer

Liao, Hong Ye; Zhang, Wen Wen; Sun, Jia; Li, Feng Yan; He, Zhenyu; Wu, San Gang

doi:10.7150/jca.22280

Cited by 66 publications

(49 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another aspect, the pathomorphological indicators, as the results of genetic changes of tumor cells, should also be well studied. Previous study had reported that specific histologic subtypes showed significant differences in the percentage of distant metastasis, and invasive lobular carcinoma was considered as a subtype with highest metastasis probability . However, another study reported that breast cancer subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status had specific preferential site of distant organ metastases .…”

Section: Introductionmentioning

confidence: 99%

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer

Wang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

| BACKGROUNDBreast cancer is one of the most common tumors among women, and the second leading cause of cancer-related death in the world. 1 Approximately 1 to 1.3 million cases are diagnosed with breast cancers worldwide every year, including approximately 60% patients with hormone receptor-positive breast cancers, 20% patients with Her2/neu receptor overexpressed cancers, and triple-negative breast cancers (TNBC) constitute approximately 20% of breast cancer cases. 2 Traditionally, TNBC encompasses a subset of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which requires special treatment Abstract Background: The distant metastasis was the most predictive characters of poor prognosis for triple-negative breast cancer (TNBC). We aimed to evaluate the correlation between patient characters and preferential distant metastatic sites (DMS) and its effects on prognosis. Methods: Using the 2010-2014 Surveillance, Epidemiology, and End Results Program (SEER) data, patients with TNBC were classified into eight histologic subtypes. Patient characters were compared using a chi-squared test. Logistic regression was used for identification of predictive factors. The log-rank testing was utilized with disease-specific survival (DSS) and overall survival (OS) as the primary outcomes. Results: A total of 23 270 patients with TNBC were involved, including 1544 patients with distant metastatic cancer. Bone metastasis was diagnosed in 559 cases, brain metastasis in 124 cases, liver metastasis found in 369 cases and lung metastasis in 492 cases. Histologic subtypes including metaplastic breast carcinoma and invasive lobular carcinoma showed significant differences in preferential DMS compared with invasive ductal carcinoma. Furthermore, we found different histologic subtypes with specific DMS showed various prognosis. We also evaluated different DMS of specific histologic subtypes showed different prognosis. Conclusion: Certain histologic subtypes of breast cancer are associated with preferential DMS and prognosis; this knowledge may help to further understand the mechanism of breast cancer metastasis and to monitor the prognosis of patients with TNBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer

Wang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Based on its biomarker [oestrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/HER2)] profile and molecular profiling, it is classified as a triple‐negative and basal‐like carcinoma . However, in contrast to other basal‐like triple‐negative mammary carcinomas and salivary gland ACCs, breast ACC in general has a favourable prognosis . A variant of breast ACC, referred to as the solid variant of ACC with basaloid features, has been reported to have a more aggressive biological behaviour …”

Section: Introductionmentioning

confidence: 99%

“…3 However, in contrast to other basal-like triple-negative mammary carcinomas and salivary gland ACCs, breast ACC in general has a favourable prognosis. [4][5][6] A variant of breast ACC, referred to as the solid variant of ACC with basaloid features, has been reported to have a more aggressive biological behaviour. [7][8][9] Studies have demonstrated that the MYB-NFIB fusion, resulting from translocation t(6;9)(q22-23; p23-24) involving the oncogene MYB on chromosome 6q and the gene for transcription factor NFIB on chromosome 9p, is specific to ACCs from various sites, including breast.…”

Section: Introductionmentioning

confidence: 99%

MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma

et al. 2018

View full text Add to dashboard Cite

Our results indicate that AMEs do not harbour MYB gene rearrangement. IHC for MYB may be helpful in diagnosing FISH-negative cases of ACC, particularly the diagnostically more difficult solid variants. However, weak to moderate MYB expression in a subset of AMEs highlights not only a potential diagnostic pitfall, but also shared pathophysiology with ACC worth investigating further at the genomic level.

show abstract

“…In recent years, combination approaches including chemotherapy, surgery, radiotherapy, targeted therapy and hormonal therapy have proven more successful than conventional single treatment methods . However, patients with TNBC, characterized by lack of expression of human epithelial growth factor receptor‐2, estrogen, progesterone receptor (ER − , PR − , Her2/neu − ) have poor prognosis . This is because therapy for TNBC patients remains limited.…”

Section: Introductionmentioning

confidence: 99%

“…3 However, patients with TNBC, characterized by lack of expression of human epithelial growth factor receptor-2, estrogen, progesterone receptor (ER À , PR À , Her2/neu À ) have poor prognosis. 4,5 This is because therapy for TNBC patients remains limited.…”

Section: Introductionmentioning

confidence: 99%

Senescent cells re‐engineered to express soluble programmed death receptor‐1 for inhibiting programmed death receptor‐1/programmed death ligand‐1 as a vaccination approach against breast cancer

Feng

et al. 2018

Cancer Science

View full text Add to dashboard Cite

Various types of vaccines have been proposed as approaches for prevention or delay of the onset of cancer by boosting the endogenous immune system. We previously developed a senescent‐cell‐based vaccine, induced by radiation and veliparib, as a preventive and therapeutic tool against triple‐negative breast cancer. However, the programmed death receptor‐1/programmed death ligand‐1 (PD‐1/PD‐L1) pathway was found to play an important role in vaccine failure. Hence, we further developed soluble programmed death receptor‐1 (sPD1)‐expressing senescent cells to overcome PD‐L1/PD‐1‐mediated immune suppression while vaccinating to promote dendritic cell (DC) maturity, thereby amplifying T‐cell activation. In the present study, sPD1‐expressing senescent cells showed a particularly active status characterized by growth arrest and modified immunostimulatory cytokine secretion in vitro. As expected, sPD1‐expressing senescent tumor cell vaccine (STCV/sPD‐1) treatment attracted more mature DC and fewer exhausted‐PD1+ T cells in vivo. During the course of the vaccine studies, we observed greater safety and efficacy for STCV/sPD‐1 than for control treatments. STCV/sPD‐1 pre‐injections provided complete protection from 4T1 tumor challenge in mice. Additionally, the in vivo therapeutic study of mice with s.c. 4T1 tumor showed that STCV/sPD‐1 vaccination delayed tumorigenesis and suppressed tumor progression at early stages. These results showed that STCV/sPD‐1 effectively induced a strong antitumor immune response against cancer and suggested that it might be a potential strategy for TNBC prevention.

show abstract

The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer

Cited by 66 publications

References 35 publications

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer

MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma

Senescent cells re‐engineered to express soluble programmed death receptor‐1 for inhibiting programmed death receptor‐1/programmed death ligand‐1 as a vaccination approach against breast cancer

Contact Info

Product

Resources

About